Emerging studies suggest Retatrutide , a dual agonist targeting both the gut-brain axis and another hormone, could represent a promising development for body loss . Preliminary human trials have demonstrated considerable losses in visceral fat , potentially surpassing other obesity medications . Despite this, additional evaluation is needed to full